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SUMMARY 
Fetal supraventricular tachycardia (SVT) can be successfully treated transplacentally, but in cases where fetal 
hydrops develops there is considerable morbidity and mortality. The present study was carried out to establish 
whether the introduction of flecainide altered obstetric management and fetal outcome. A retrospective analysis 
took place of 51 singleton pregnancies which were referred to the division of prenatal diagnosis because of fetal 
tachycardia between 1982 and 1993. SVT was documented in 50 out of 51 fetuses, one of which displayed a 
combination of extensive rhabdomyomas and severe hydrops and died shortly after referral. In the other fetus 
ventricular tachycardia was diagnosed. Of the remaining 49 fetuses, 14 did not receive any prenatal treatment, but 
nine needed postnatal treatment. Transplacental treatment of SVT took place in 35 fetuses, of which 22 presented 
without hydrops and 13 with hydrops. These subsets differed significantly with respect to restoration of normal 
sinus rhythm (73% vs. 30%; p<O-OOl) and mortality (0% vs. 46%; p<O.OOl). Digoxin was effective in restoring 
sinus rhythm in 55 per cent of the non-hydropic fetuses but in only eight per cent of the hydropic fetuses. 
Flecainide was effective in restoring sinus rhythm in all non-hydropic fetuses where digoxin treatment failed, and 
in 43 per cent of hydropic fetuses. Administration of flecainide resulted in a significantly reduced mortality 
(p<O*OOl) compared with digoxin treatment. No adverse effects were seen. Postnatal anti-arrhythmic treatment 
was necessary in 23 infants. Treatment could be withdrawn within one year in all cases but one. 
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INTRODUCTION 
Fetal tachycardia is a rare but challenging dis- 
order and is usually of supraventricular origin. In 
most cases there is no underlying structural 
abnormality, although atrial septal aneurysm has 
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been associated with supraventricular tachycardia 
(SVT) (Stewart and Wladimiroff, 1988). Fre 
quently, there is an association with Wolff 
Parkinson White (WPW) syndrome, but it may also 
arise from fetal myocarditis as a result of a viral 
infection (KO et d., 1992). If untreated, SVT may 
lead to fetal hydrops and fetal or early neonatal 
death. An accurate diagnosis of the nature of the 
rhythm disturbam can be made by M-mode 
echocardiography (Allan et al., 1983). Digoxin has 
been the drug of choice for treating SVT (Kleinman 
et aZ., 1985). It is administered to the mother and 
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reaches the fetus transplacentally. In the presence of 
fetal hydrops placental transfer is diminished, often 
resulting in treatment failure. When digoxin fails to 
restore normal sinus rhythm (SR) several other 
drugs have been used, such as propranolol, 
kinidine, procainamide, verapamil and amiodarone, 
either given to the mother or directly to the fetus 
(Amoux et al., 1987; Maxwell et al., 1988; 
Hansmann er al., 1991; Hallak et al., 1991; Jouppila 
et al., 1993). After the introduction of flecainide in 
1988 adverse effects have been noted, especially in 
adults after myocardial infarction (Editorial, N. 
Engl. J. Med., 1989; Fish et al., 1991). We have 
retrospectively analysed the clinical presentation, 
treatment and outcome of a consecutive series of 49 
patients with fetal SVT, with emphasis on the 
question as to whether the introduction of flecainide 
altered policy and outcome. 
MATERIALAND METHODS 
We retrospectively studied the clinical data of 
51 single pregnancies that were referred to the 
Division of Prenatal Diagnosis because of fetal 
tachycardia during the period 1982-1993. 
Gestational age ranged between 16 and 41 weeks 
(mean: 30 f 5.8 (fSD) wks). Pregnancy was 
otherwise uncomplicated in 49 cases, insulin 
dependent juvenile diabetes or pregnancy diabetes 
was present in the remaing two cases. Blood 
samples were taken from all women to assess 
possible viral infections. Cardiological exami- 
nation of each pregnant woman was carried-out 
before transplacental treatment of the fetal 
tachycardia was initiated. 
Fetal tachycardia was diagnosed by simulta- 
neous M-mode recording of atrial and ventricular 
cardiac activity using a Diasonics CV 1 0 0  (carrier 
frequency 3.5 MHz)  or a Toshiba SSA 270 (carrier 
frequency 3.5 MHz). All fetuses were screened for 
structural abnormalities and for the presence of 
hydrops, which was considered to be present 
whenever there was pericardial or pleural effusion 
or when ascites was noted. 
Management of fetal tachycardia was docu- 
mented. To restore fetal sinus rhythm, digoxin was 
the first drug of choice. After maternal admini- 
stration of a loading dose of 1 mg, a maintenance 
dose of 025 mg, three times a day, was given. 
Serum drug concentrations were measured and the 
dosage adjusted to maintain concentrations around 
2 nanograms/milliliter (ng/ml). When sinus rhythm 
could not be achieved other drugs were admi- 
nistered to the pregnant woman such as verapamil; 
or occasionally propranolol, procainamide or 
amiodarone. As from January 1991, flecainide was 
selected as the first drug of choice in cases of fetal 
hydrops, and was also administered if treatment 
with digoxin failed to restore sinus rhythm in the 
non-hydropic fetus. Flecainide was administered 
orally 3 times 100 mg a day; the dosage was 
adjusted if necessary to keep serum drug 
concentrations between 0.5-1 microgram/milliliter 
(mcg/ml). 
Gestational age at referral as well as time, mode 
and place of delivery and fetal outcome were 
documented. Neonatal heart rate was recorded by 
ECG, which was analysed for pre-excitation. 
Medication and duration of therapy were noted. 
Statistical analysis was performed using 
Fisher’s exact test. Statistical significance was set 
at p<005. 
RESULTS 
Fifty fetuses demonstrated SVT, 14 of which 
presented as atrial flutter (28%). Hydrops was 
present in 17 fetuses (34%). Anti-arrhythmic treat- 
ment was not initiated in one fetus because of 
extensive rhabdomyomas and severe hydrops; 
fetal death occurred two days later. Another fetus 
displayed ventricular tachycardia (Polak er al., 
1989). Both these fetuses were eliminated from 
the follow-up. An atrial septal aneurysm was 
established in three fetuses. No other structural 
abnormalities were found and no viral infections 
were documented. 
Of the remaining 49 fetuses, 35 were managed 
by transplacental medication. Reasons for not 
treating the other 14 fetuses are summarized in 
Table I. There was no mortality in this group. Nine 
of these infants needed anti-arrhythmic therapy 
after birth. Six infants received digoxin in treat- 
ment alone, three infants needed a combination of 
digoxin and propranolol. A small muscular ventri- 
cular septal defect proved to be present in one 
infant, which later closed spontaneously. Follow- 
up showed normal development of all these 
infants. 
Data on the 35 treated fetuses are shown in 
Figures I and 2. Two groups could be distin- 
guished according to t k  presence or absence of 
fetal hydrops. In 22 fetuses there was no hydrops 
(Figure 1). Digoxin was the first drug of choice, 
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Table I-Data on 14 fetuses with supraventicular tachycardia (SVT) which did not receive transplacental anti- 
arrhythmic treatment 
Fetuses not treated 
(n- 14) 
- intennittent SVT 7 
- in labour (2 37 wks) 2 
- induction of labour (37.5 wks) 1 
- severe hydrops in advanced pregnancy (32-36 wks) 
Caesarean section 
4 
Moaality: 0 
which resulted in sinus rhythm in 12 fetuses. 
Flecainide was given to four fetuses in whom 
digoxin therapy was not effective, restoring sinus 
rhythm in all. In five out of the remaining six 
cases, pregnancy was terminated by means of 
Caesarean section with the aim of controlling SVT 
postnatally. In the other fetus, SVT was inter- 
mittent and expectant obstetric management was 
adopted. There were no signs of pre-excitation 
postnatally. There was no mortality in this group. 
Postnatal treatment was necessary in 19 infants. In 
17 infants digoxin alone was sufficient to control 
normal rhythm. In two infants with SVT flecainide 
was given after digoxin failure. These two infants 
had also not reacted to digoxin prenatally. 
Postnatal treatment was discontinued after one 
week in one case because of bradycardia. In all 
other cases, therapy was discontinued after one 
year, without recurrence of SVT. 
Hydrops was present in 13 fetuses (Figure 2). 
Initiation of digoxin therapy resulted in sinus 
rhythm in one fetus. Before the introduction of 
flecainide in 1991, a range of other anti-arryhthmic 
drugs was used in five fetuses, which were 
ineffective in establishing sinus rhythm. All five 
fetuses died. Of the seven fetuses that were 
managed by flecainide, three developed sinus 
rhythm. In the other four fetuses it was decided to 
perform a Caesarean section, because of ongoing 
tachycardia and progressive hydrops. In these 
instances, gestational age (28-35 wks) was 
considered to be sufficiently advanced to promote 
delivery and thus create the possibility of treating 
the infants directly. Of the seven newborn which 
presented with hydrops, all but one needed 
treatment. 'Iho infants remained in sinus rate by 
digoxin alone, in one case propranolol was added. 
In two infants, flecainide was continued. In these 
infants therapy could be withdrawn after one year 
without recumnce of SVT. In another infant, which 
a p p e d  to have an ectopic atrial tachycardia and 
was difficult to manage prenatally, control of heart 
rate was finally achieved by sotacor. When this 
medication was withdrawn after two years there 
was a reccurrence of SVT within six months, 
necessitating further sotacor medication. One infant 
died on the second day after delivery because of 
complications of ongoing tachycardia and severe 
hydrops at 31 weeks of gestation. Overall mortality 
in the hydropic group was 46 per cent. 
The two groups differed significantly with 
respect to restoration of normal sinus rhythm: 73% 
in the non-hydropic group versus 30 per cent in 
the hydropic group (p<O.OOl), and mortality: 0% 
in the non-hydropic group versus 46 per cent in 
the hydropic group (p<O-OOl). 
When comparing the efficacy of digoxin and 
flecainide, it can be seen that digoxin was effective 
in restoring sinus rhythm in 55 per cent of the non- 
hydropic fetuses. In cases of digoxin failure, 
flecainide proved to be effective in all non- 
hydropic fetuses (p<0.05). Flecainide was also 
effective in restoring sinus rhythm in 43 per cent 
of the hydropic fetuses, while digoxin converted 
SVT to sinus rhythm in only one of the hydropic 
fetuses (8 per cent). This difference was, however, 
not significant. Mortality was significantly redu- 
ced in the hydropic fetuses after the introduction 
of flecainide (p<O*OOl). No adverse effects were 
seen with either digoxin or flecainide. 
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Fig. &Data on 13 hydropic fetuses with supraventricular 
tachycardia (SVT) receiving transplacental anti-arrhythmic treat- 
ment SR=sinus rhythm; CSSaesarean section; R-eatrnent 
DISCUSSION 
A retrospective analysis of treatment modalities 
for fetal SVT is presented. Emphasis was put on 
the anti-anrhythmic agents digoxin and flecainide. 
It is demonstrated that fetal hydrops is a strong 
prognostic determinant of fetal SVT. The present 
study shows that mortality was 35 per cent in the 
presence of hydrops as opposed to nil in the non- 
hydropic fetus. This is in agreement with other 
reports (Bergmans et al., 1985; Maxwell et al., 
1988; Hansmann et al., 1991; van Engelen et al., 
1994). In addition, conversion into sinus rhythm 
was considerably less successful in the presence of 
fetal hydrops. 
The success rate of digoxin turned out to be 
lower in hydropic fetuses than in non-hydropic 
fetuses (Younis and Granat, 1987; Hallak et al., 
199 1). We experienced a clear association between 
pre- and postnatal success rates of both drugs in 
individual cases, especially with regard to 
ectopic atrial tachycardia being difficult to treat 
(Kleinman et al., 1985; Azancot-Benisty et al., 
1992). 
Digoxin has been the drug of choice in the 
treatment of fetal SVT (Kleinman et al., 1985; 
Allan et al., 1991). Flecainide is a potent class Ic 
antiarrhythmic drug, which has been used in 
infants with SVT since 1988 (Wren and Hunter, 
1988). In 1991, favourable results were published 
in a first series of 14 cases of fetal tachycardia 
treated with flecainide (Allan et al., 1991). At the 
same time serious side effects were reported from 
the use of flecainide in patients who had suffered 
a myocardial infarction (Editorial, N. Engl. J. 
Med., 1989) and restricted use of flecainide was 
recommended (Perry et al., 1989; Epstein, 1989; 
Fish et aL, 1991). In our centre flecainide was 
introduced in the treatment of fetal SVT in 1991. 
Flecainide proved to be more successful in 
converting fetal SVT into sinus rhythm in cases 
in which digoxin treatment had failed and in 
cases presenting with fetal hydrops. Similar 
observations were made elsewhere (Perry et al., 
1991; Kofinas et aL, 1991; Mills, 1992). We did 
not experience any adverse effects. A similar 
experience was reported elsewhere in a series of 
fetuses and infants with SVT (Perry and Garson, 
1992; van Engelen et al., 1994). 
In fetal hydrops due to arrhythmia a variety of 
other drugs have been suggested. Verapamil is a 
calcium antagonist, which is known for its serious 
side effects in the neonate and infant, of which 
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asystole is the most important (Garson, 1987). In 
the five cases in which we used verapamil, it was 
concluded that fetal death was clearly related to 
this drug in one fetus which died in utero two 
hours after an intravenous dose of 10 mg of 
verapamil to the mother. Another fetus died 
suddenly in utero eight days after conversion to 
sinus rhythm following 14 days of treatment with 
digoxin and verapamil. A case of fetal death 
following successful conversion of fetal SVT with 
digoxin and verapamil has been reported else- 
where (Owen et al., 1988). Therefore, in our 
opinion the use of verapamil in fetal SVT should 
be avoided, as has also been suggested by others 
(Garson, 1987; Kleinman and Copel, 1991). 
Amiodarone is a class III antiarrhythmic drug with 
a long elimination time. It has been used in 
maternal therapy, but also in direct fetal therapy, 
avoiding transplacental transfer (Jouppila et al., 
1993). This drug is known for its adverse effects, 
especially on the developing thyroid gland (de 
Wolf et al., 1988). In our series amiodarone was 
used only once, and did not achieve conversion to 
sinus rhythm. 
Fetal tachycardia is usually of supraventricular 
origin, and only very rarely is a ventricular 
tachycardia diagnosed. Structural abnormalities 
are seldom found in fetal SVT, although cardiac 
tumours and atrial septal aneurysm have been 
associated with SVT. SVT may also be related to 
fetal myocarditis or pre-excitation syndrome. In 
our series structural abnormalities were found in 
only five out of 51 fetuses. One fetus, with 
extensive rhabdomyomas died in utero. In another 
infant a small muscular ventricular septal defect 
was diagnosed after birth, which was probably 
unrelated to the tachycardia. An atrial septal 
aneurysm was established in three fetuses. The 
low incidence of atrial aneurysm in our series does 
not support the findings of others that these 
aneurysms could play an etiological role in the 
development of SVT. No viral infections were 
documented in our study group. Postnatal ECG 
showed pre-excitation syndrome in four infants (8 
per cent). It has recently been demonstrated in 
pediatric patients that an accessory connection is 
the most frequent mechanism of SVT (73 per cent) 
(KO et al., 1992). Since normal AV-conduction 
may occur in the presence of a pre-excitation 
syndrome, a normal postnatal ECG does not rule 
out the presence of this syndrome. It is likely that 
additional infants will prove to have this feature 
later in life. 
It can be concluded that, in our series, 
flecainide was shown to be more successful than 
digoxin in restoring sinus rhythm during fetal 
SVT. In the absence of fetal hydrops digoxin is a 
potent drug for the conversion of tachycardia into 
sinus rhythm. Where digoxin fails to restore sinus 
rhythm, flecainide may be successful. In hydropic 
fetuses there is a high risk of perinatal mortality, 
since transplacental drug transfer is hampered and 
digoxin, therefore, appears to be of limited value. 
Verapamil has serious side effects and should be 
avoided as a mode of treatment. Furthermore, in 
our experience, administration of flecainide is 
associated with a significant reduction in perinatal 
mortality, with no adverse side effects being 
observed. 
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